首页> 外文期刊>Obstetrical and gynecological survey >Risk Factors for Readmission in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Who Are Receiving Front-line Chemotherapy on a Clinical Trial (GOG 218): An NRG Oncology/Gynecologic Oncology Group Study (ADS-1236) EDITORIAL COMMENT

【24h】

Risk Factors for Readmission in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Who Are Receiving Front-line Chemotherapy on a Clinical Trial (GOG 218): An NRG Oncology/Gynecologic Oncology Group Study (ADS-1236) EDITORIAL COMMENT

机译：在临床试验中接受一线化疗的卵巢癌，输卵管癌和原发性腹膜癌患者再次入院的危险因素（GOG 218）：NRG肿瘤/妇科肿瘤学组研究（ADS-1236）编辑评论

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Obstetrical and gynecological survey》 |2016年第1期|共4页
作者
Van Le Linda;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类妇产科学;
关键词

相似文献

外文文献
中文文献

1. Risk Factors for Readmission in Patients With Ovarian, Fallopian Tube, and Primary Peritoneal Carcinoma Who Are Receiving Front-line Chemotherapy on a Clinical Trial (GOG 218): An NRG Oncology/Gynecologic Oncology Group Study (ADS-1236) EDITORIAL COMMENT [J] . Van Le Linda Obstetrical and gynecological survey . 2016,第1期

机译：在临床试验中接受一线化疗的卵巢癌，输卵管癌和原发性腹膜癌患者再次入院的危险因素（GOG 218）：NRG肿瘤/妇科肿瘤学组研究（ADS-1236）编辑评论
2. Cognitive function during and six months following chemotherapy for front-line treatment of ovarian, primary peritoneal or fallopian tube cancer: An NRG oncology/gynecologic oncology group study [J] . Hess Lisa M., Huang Helen Q., Hanlon Alexandra L., Gynecologic Oncology: An International Journal . 2015,第3期

机译：一线治疗卵巢癌，原发性腹膜癌或输卵管癌的化疗期间及之后六个月的认知功能：NRG肿瘤/妇科肿瘤小组研究
3. Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Müllerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group [J] . Noriyuki Katsumata1 Yasuhiro Fujiwara1 Toshiharu Kamura2 Toru Nakanishi3 Masayuki Hatae4 Daisuke Aoki5 Kenichi Tanaka6 Hiroshi Tsuda7 Shoji Kamiura8 Kazuhiro Takehara9 Toru Sugiyama10 Junzo Kigawa11 Keiichi Fujiwara12 Kazunori Ochiai13 Ryo Ishida14 Mitsuo Inagaki14 and Kiichiro Noda15 Japanese Journal of Clinical Oncology . 2008,第11期

机译：聚乙二醇化脂质体阿霉素（JNS002）在日本米勒癌（上皮性卵巢癌，输卵管原发癌，腹膜癌）患者中的铂类化学疗法的II期临床试验：日本妇科肿瘤学的II期研究组
4. Risk factors for readmission in patients with ovarian fallopian tube and primary peritoneal carcinoma who are receiving front-line chemotherapy on a clinical trial (GOG 218): an NRG oncology/gynecologic oncology group study (ADS-1236) [O] . Linda R. Duska, James J. Java, David E. Cohn, -1

机译：在临床试验中接受一线化疗的卵巢癌输卵管癌和原发性腹膜癌患者再次入院的危险因素（GOG 218）：NRG肿瘤/妇科肿瘤组研究（ADS-1236）
5. Phase II Clinical Trial of Pegylated Liposomal Doxorubicin (JNS002) in Japanese Patients with Müllerian Carcinoma (Epithelial Ovarian Carcinoma, Primary Carcinoma of Fallopian Tube, Peritoneal Carcinoma) Having a Therapeutic History of Platinum-based Chemotherapy: A Phase II Study of the Japanese Gynecologic Oncology Group [O] . Katsumata, Noriyuki, Fujiwara, Yasuhiro, Kamura, Toshiharu, 2008

机译：聚乙二醇化脂质体阿霉素（JNS002）在日本米勒癌（上皮性卵巢癌，输卵管原发癌，腹膜癌）患者中的铂类化学疗法的II期临床试验：日本妇科肿瘤学的II期研究组

获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

客服微信
服务号